RJF Laboratorio Reig Jofre, S.A.

2.874USD2.620 EUR · BME+0.38%Mkt Cap: 235.86M USDP/E: 52.40

Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products, raw materials, biotechnological products, nutritional supplements, health products, medical…

Key Statistics

Company
Market Cap235.86M USD
Enterprise Value356.41M USD
Revenue (TTM)361.98M USD
Gross Profit214.80M USD
Net Income (TTM)5.51M USD
Revenue/Share4.46 USD
Last Price2.874 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees1.4K
CountryES
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINES0165359029
Valuation
P/E (Trailing)52.40
P/E (Forward)52.40
PEG0.58
EV/EBITDA19.00
EV/Revenue0.98
P/S0.65
P/B0.98
EPS (TTM)0.05 USD
EPS (Forward)0.05 USD
52W Range
2.54548% of range3.225
52W High3.225 USD
52W Low2.545 USD
Profitability
Gross Margin59.15%
Oper. Margin-0.19%
EBITDA Margin5.18%
Profit Margin1.52%
ROE2.30%
ROA1.27%
ROIC1.82%
ROCE2.32%
Growth
Revenue Growth-2.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF1.66M USD
CapEx (TTM)20.08M USD
FCF Margin—
FCF Yield—
Net Debt119.88M USD
Net Debt/EBITDA6.39
Net Debt/FCF—
Balance Sheet
Debt/Equity0.42
Current Ratio1.44
Quick Ratio0.75
Book Value/Sh2.94 USD
Cash/Share0.25 USD
Dividends
Fwd Div Rate0.02 USD
Trail. Div Rate0.00 USD
Div. Yield0.92%
5Y Avg Yield1.46%
Payout Ratio30.00%
Ex-Div DateMay 21, 2026
Pay Date—
Splits
Last Split1:20
Split DateSep 22, 2015
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.82.08M
Float21.96M
Insiders78.46%
Institutions5.85%
Technical
SMA 502.851 (+0.8%)
SMA 2002.891 (-0.6%)
Beta0.94
S&P 52W Chg12.00%
Avg Vol (30d)9.59K
Avg Vol (10d)8.33K
Technical Indicators
RSI (14)54.9
MACD0.0028
MACD Signal-0.0019
MACD Hist.+0.0046
BB Upper2.897 USD
BB Middle2.840 USD
BB Lower2.783 USD
BB Width4.01%
ATR (14)0.0461 USD
Vol Ratio (20d)2.52x

About Laboratorio Reig Jofre (BME: RJF)

›

Laboratorio Reig Jofre (BME: RJF) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 1,400 employees.

The shares were at 2.620 EUR on 19 November 2026, down 3.3% over 52 weeks. Its 52-week range is 2.320 EUR to 2.940 EUR: the price is 10.9% below the high and 12.9% above the low.

At a market capitalisation of 215.05M EUR, it trades at 52.4 times trailing earnings and 52.4 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a premium of 112% for RJF. It pays a dividend yielding 0.92% (it pays out 30% of its earnings), against a median of 1.90% among the dividend payers in that peer group.

Laboratorio Reig Jofre reports return on equity of 2.3%, an operating margin of -0.2% and revenue down 2.8% year over year.

Its debt exceeds its cash by 109.30M EUR, a debt-to-equity ratio of 0.42. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.